FuelCell Energy Inc vs Sana Biotechnology Inc — how do they compare? FuelCell Energy Inc trades at $19.62 (market cap $1.54B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: FuelCell Energy Inc is the larger of the two by market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | SANA | |
|---|---|---|
Market Cap | $1.54B | $1.13B |
Sector | Industrials | Health |
52-Week High | $36.01 | $5.92 |
52-Week Low | $3.92 | $2.68 |
Enterprise Value | $1.38B | $1.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.52, up 3.23% with a bullish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn improved in 2026. Recent positive developments include clinical data presentations and a $69M stock offering. Analyst consensus remains strong with 82% buy ratings and a $9.50 price target.
While SANA shows promising clinical progress and strong analyst support, significant financial losses and cash burn present substantial risks. The stock's upside potential depends on successful clinical trial outcomes and path to profitability, making it suitable for risk-tolerant investors seeking biotech exposure.
Trailing returns across standard periods
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →